Abivax (CHIX:ABVXP) Total Liabilities : €131.05 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Total Liabilities?

Abivax's Total Liabilities for the quarter that ended in Dec. 2023 was €131.05 Mil.

Abivax's quarterly Total Liabilities increased from Dec. 2022 (€68.36 Mil) to Jun. 2023 (€90.59 Mil) and increased from Jun. 2023 (€90.59 Mil) to Dec. 2023 (€131.05 Mil).

Abivax's annual Total Liabilities declined from Dec. 2021 (€83.30 Mil) to Dec. 2022 (€68.36 Mil) but then increased from Dec. 2022 (€68.36 Mil) to Dec. 2023 (€131.05 Mil).

Abivax Total Liabilities Historical Data

The historical data trend for Abivax's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Total Liabilities Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

33.14

53.40

83.30

68.36

131.05

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															83.30	65.56	68.36	90.59	131.05

Abivax Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Abivax's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	70.041	+	(44.857	+	15.525
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.629)
	=	131.05

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	327.062	-	196.01
	=	131.05

Abivax's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	70.041	+	(44.857	+	15.525
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.629)
	=	131.05

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	327.062	-	196.01
	=	131.05

Abivax Total Liabilities Related Terms

Thank you for viewing the detailed overview of Abivax's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax (CHIX:ABVXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (CHIX:ABVXp) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X10:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.

Abivax (CHIX:ABVXP) Headlines

No Headlines